SCHEMBL4882863

SCHEMBL4882863

COc1ccc(C2CCNCC2)cn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 5/20 0.47
NTRK1 P04629 1/20 0.46
CSF1R P07333 1/20 0.46
NTRK2 Q16620 1/20 0.46
TLR9 Q9NR96 3/20 0.46
TLR8 Q9NR97 3/20 0.46
TLR7 Q9NYK1 3/20 0.46
CHRNB2 P17787 1/20 0.46
CHRNA4 P43681 1/20 0.46
PLAT P00750 1/20 0.46
DDB1 Q16531 1/20 0.44
CRBN Q96SW2 1/20 0.44
TGFBR1 P36897 1/20 0.43
ACVR1 Q04771 1/20 0.43
SLC18A3 Q16572 1/20 0.43
SIGMAR1 Q99720 1/20 0.43
JAK2 O60674 1/20 0.43
JAK3 P52333 1/20 0.43
PTK2 Q05397 1/20 0.43
QDPR P09417 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL23130915 0.98 HTR2C (0.49) HTR2CNTRK1CSF1RNTRK2TLR9
SCHEMBL3924233 0.90 PDE4B (0.48) CHRNB2CHRNA4PLAT
SCHEMBL167849 0.88 TRPV6 (0.46) CSF1RCHRNB2CHRNA4SLC6A2SLC6A4
SCHEMBL2081590 0.86 CHRNB2 (0.41) NTRK1CSF1RNTRK2TLR9TLR8
SCHEMBL16475195 0.84 PDGFRB (0.44) CHRNB2CHRNA4SLC6A2SLC6A4SLC6A3
SCHEMBL16475192 0.84 PDGFRB (0.47) CHRNB2CHRNA4SLC6A2SLC6A4SLC6A3
SCHEMBL12975683 0.84 DDB1 (0.42) HTR2CNTRK1CSF1RNTRK2TLR9
SCHEMBL5182802 0.83 KDM4E (0.50) CHRNB2CHRNA4SLC6A2SLC6A4SLC6A3
SCHEMBL20757728 0.83 CHRNB2 (0.46) CSF1RCHRNB2CHRNA4SLC6A2SLC6A4
SCHEMBL31076325 0.83 CHRNB2 (0.46) CSF1RCHRNB2CHRNA4SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12479816-B2 20-HETE formation inhibitors University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2025-11-25 US disclosed
US-20220144797-A1 20-HETE FORMATION INHIBITORS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2022-05-12 US disclosed
US-20220144797-A1 20-HETE FORMATION INHIBITORS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2022-05-12 US disclosed
WO-2020163689-A1 20-HETE FORMATION INHIBITORS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2020-08-13 WO disclosed
WO-2020163689-A1 20-HETE FORMATION INHIBITORS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2020-08-13 WO disclosed
US-8754107-B2 Aminopyrrolidines as chemokine receptor antagonists ABBVIE INC. (US) 2014-06-17 US disclosed
US-20080176883-A1 Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone ABBVIE INC. 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176883-A1 Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone MIF, CCL5, CCR2 HTR2C 855/4885NTRK1 815/4885CSF1R 114/4885
US-20220144797-A1 20-HETE FORMATION INHIBITORS CYP4A22, ALOX5, ALOX15 HTR2C 235/4885NTRK1 2851/4885CSF1R 4580/4885
US-12479816-B2 20-HETE formation inhibitors CYP4A22, ALOX5, ALOX15 HTR2C 235/4885NTRK1 2851/4885CSF1R 4580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.